Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

698 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients.
Castagna L, Busca A, Bramanti S, Raiola Anna M, Malagola M, Ciceri F, Arcese W, Vallisa D, Patriarca F, Specchia G, Raimondi R, Devillier R, Furst S, Giordano L, Sarina B, Mariotti J, Olivieri A, Bouabdallah R, Carlo-Stella C, Rambaldi A, Santoro A, Corradini P, Bacigalupo A, Bonifazi F, Blaise D. Castagna L, et al. Among authors: rambaldi a. BMC Cancer. 2020 Nov 24;20(1):1140. doi: 10.1186/s12885-020-07602-w. BMC Cancer. 2020. PMID: 33234127 Free PMC article.
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Corradini P, et al. Among authors: rambaldi a. Blood. 2002 Jan 1;99(1):75-82. doi: 10.1182/blood.v99.1.75. Blood. 2002. PMID: 11756155 Free article.
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, Rambaldi A, Cortelazzo S, Patti C, Parvis G, Benedetti F, Capria S, Corradini P, Tarella C, Barbui T. Gianni AM, et al. Among authors: rambaldi a. Blood. 2003 Jul 15;102(2):749-55. doi: 10.1182/blood-2002-08-2476. Epub 2003 Mar 27. Blood. 2003. PMID: 12663455 Free article.
Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B, Rambaldi A, Morello E, Narni F, Santarone S, Locatelli F, Bacigalupo A; Gruppo Italiano Trapianto Midollo Osseo (GITMO). Falda M, et al. Among authors: rambaldi a. Am J Hematol. 2007 Oct;82(10):863-6. doi: 10.1002/ajh.20990. Am J Hematol. 2007. PMID: 17616972 Free article. Clinical Trial.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Ladetto M, et al. Among authors: rambaldi a. Blood. 2008 Apr 15;111(8):4004-13. doi: 10.1182/blood-2007-10-116749. Epub 2008 Jan 31. Blood. 2008. PMID: 18239086 Free article. Clinical Trial.
Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, Blaise D, Rocha V; Acute Leukemia Working Party; European Group for Blood and Marrow Transplantation. Mohty M, et al. Among authors: rambaldi a. Haematologica. 2008 Feb;93(2):303-6. doi: 10.3324/haematol.11960. Haematologica. 2008. PMID: 18245655 Free article.
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A. Tarella C, et al. Among authors: rambaldi a. J Clin Oncol. 2008 Jul 1;26(19):3166-75. doi: 10.1200/JCO.2007.14.4204. Epub 2008 May 19. J Clin Oncol. 2008. PMID: 18490650
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, Bernardi M, Iori AP, Rambaldi A, Cerretti R, Marenco P, Pioltelli P, Malcovati L, Pascutto C, Oneto R, Fanin R, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Alessandrino EP, et al. Among authors: rambaldi a. Blood. 2008 Aug 1;112(3):895-902. doi: 10.1182/blood-2008-03-143735. Epub 2008 May 22. Blood. 2008. PMID: 18497321 Free article.
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.
Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M, Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. Bruno B, et al. Among authors: rambaldi a. Blood. 2009 Apr 2;113(14):3375-82. doi: 10.1182/blood-2008-07-167379. Epub 2008 Dec 8. Blood. 2009. PMID: 19064724 Free PMC article. Clinical Trial.
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Bassan R, et al. Among authors: rambaldi a. Blood. 2009 Apr 30;113(18):4153-62. doi: 10.1182/blood-2008-11-185132. Epub 2009 Jan 13. Blood. 2009. PMID: 19141862 Free article.
698 results